...
首页> 外文期刊>Allergy >Lolium perenne Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients
【24h】

Lolium perenne Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients

机译:Lolium perenne lolium perenne肽免疫疗法是良好的耐受性,并引发季节性过敏性鼻炎患者的保护性B细胞反应

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Systemic allergic reactions are a risk for allergen immunotherapy that utilizes intact allergen preparations. We evaluated the safety, efficacy and immune mechanisms of short‐course treatment with adjuvant‐free Lolium perenne peptides (LPP) following a 6‐week dose‐escalation protocol. Methods In a prospective, dose‐escalation study, 61 grass pollen–allergic patients received 2 subcutaneous injections of LPP once weekly for 6?weeks. Safety was assessed evaluating local reactions, systemic reactions and adverse events. The clinical effect of LPP was determined by reactivity to the conjunctival provocation test (CPT). Specific IgE, IgG 4 and blocking antibodies were measured at baseline (V1), during (V6) and after treatment (V8). Results No fatality, serious adverse event or epinephrine use was reported. Mean wheal diameters after injections were 0.6?cm and mean redness diameters 2.5?cm, independent of dose. Transient and mostly mild adverse events were reported in 33 patients. Two patients experienced a grade I and 4 patients a grade II reaction (AWMF classification). At V8, 69.8% of patients became nonreactive to CPT. sIgG 4 levels were higher at V6 (8.1‐fold, P? ? .001) and V8 (12.2‐fold, P? ? .001) than at V1. The sIgE:sIgG 4 ratio decreased at V6 (?54.6%, P? ? .001) and V8 (?71.6%, P? ? .001) compared to V1. The absolute decrease in IgE‐facilitated allergen binding was 18% ( P? ? .001) at V6 and 25% ( P? ? .001) at V8. Conclusion Increasing doses of subcutaneous LPP appeared safe, substantially diminished reactivity to CPT and induced blocking antibodies as early as 4?weeks after treatment initiation. The benefit/risk balance of LPP immunotherapy remains to be further evaluated in large studies.
机译:None

著录项

  • 来源
    《Allergy》 |2018年第6期|共9页
  • 作者单位

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Department of Oto‐Rhino‐LaryngologyTechnical University DresdenDresden Germany;

    Department of Oto‐Rhino‐LaryngologyTechnical University DresdenDresden Germany;

    Laboratory of Brussels University HospitalsBrugmann University Hospital ULBBrussels Belgium;

    ASIT biotech s.a.Brussels Belgium;

    ASIT biotech s.a.Brussels Belgium;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    Institute of Medical Statistics Informatics and Epidemiology (IMSIE)University of CologneCologne;

    ASIT biotech s.a.Brussels Belgium;

    Immunomodulation and Tolerance GroupImperial CollegeLondon UK;

    Immunomodulation and Tolerance GroupImperial CollegeLondon UK;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    allergen; grass pollen peptides; safety; subcutaneous immunotherapy; tolerability;

    机译:过敏原;草花粉肽;安全;皮下免疫疗法;可耐受性;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号